Goji Berries for Health & Longevity - Quick Reference Sheet

Goji Berries for Health & Longevity

Created on 08/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 Audit

Whole dried berries, not juice or an isolated extract, shift blood fat readings favourably and substantially raise the yellow pigment the eye stores in its central patch, while markers of oxidative damage fall. Blood sugar and older-adult vaccine response are supported but smaller. Mood, energy, sleep and waist claims rest on weaker studies. Bleeding cases occurred with blood-thinning medication. (Full Review)

Protocol

Standard whole-fruit protocol
15 g/day
Whole dried berries eaten with main meals
Higher-dose macular protocol
28 g/day, five times weekly
Roughly double the cardiovascular dose, for an eye-specific endpoint
Best time of day
Largest fat-containing meal
Carotenoid absorption is fat-dependent
Time to effect
Plasma pigment levels
28 days
More than double
Macular pigment density
90 days
Nothing here is perceptible within a week
Lipid changes
45 days
Established by 16 weeks

Benefits

Contraindications
  • Warfarin or another vitamin K antagonist (regardless of INR stability)
  • Documented goji berry allergy, or lipid transfer protein sensitisation with prior reaction to peach, apple or other Rosaceae fruit
  • Latex-fruit syndrome with prior systemic reaction
  • Pregnancy
  • Scheduled surgery within 14 days
  • Active autoimmune disease under immunosuppression
Key Interactions
  • Direct oral anticoagulants (apixaban, rivaroxaban, edoxaban, dabigatran)
  • Antiplatelet drugs (aspirin, clopidogrel, ticagrelor)
  • Narrow-index CYP2C9 substrates (phenytoin, glipizide, celecoxib)
  • Glucose-lowering medication (metformin, sulfonylureas, insulin)
  • Over-the-counter agents (ibuprofen, naproxen, high-dose aspirin, cimetidine)
  • Supplements with additive bleeding risk (fish oil, ginkgo, garlic extract, high-dose vitamin E, nattokinase, curcumin)
  • Supplements with additive glucose lowering (berberine, chromium, alpha-lipoic acid, cinnamon extract)
  • Carotenoid supplements (lutein, zeaxanthin, astaxanthin, beta-carotene)
  • Other interventions (time-restricted eating, very-low-fat diets)

Risk & Side Effects

  • High: Potentiation of warfarin and bleeding
  • Medium: Immediate-type allergy and anaphylaxis
  • Low: Inhibition of drug-metabolising enzymes; sugar load from the dried fruit; gastrointestinal intolerance; pesticide and heavy-metal residues
  • Speculative: Pro-oxidant effect at high concentrations; immune activation in autoimmune disease

Monitoring

Marker Target Why
Triglycerides Under 80 mg/dL Most reliably moved lipid fraction
HDL cholesterol Above 60 mg/dL Second fraction that rises in pooled trials
Fasting glucose 75–86 mg/dL Captures the modest glycaemic effect
HbA1c 4.8–5.2% Confirms a real glycaemic shift rather than a single-day reading
ALT Under 20 U/L men, under 17 U/L women Tracks the liver-enzyme signal
GGT Under 20 U/L Second liver enzyme moved in trial data
Macular pigment optical density 0.45 or above at 0.5° eccentricity The endpoint behind the strongest mechanism
INR 2.0–3.0 only if anticoagulated Detects the one documented serious interaction
hs-CRP Under 1.0 mg/L Contextualises the oxidative-stress claim against background inflammation

Cadence: Lipids, fasting glucose, HbA1c, liver panel and — where the eye is the reason for use — macular pigment optical density before starting; repeat lipids and fasting glucose at 8 weeks and again at 16 weeks, then every 6–12 months once stable; recheck macular pigment at 6 months and annually thereafter; recheck the liver panel annually.

Qualitative Assessment

  • Contrast sensitivity and glare recovery when driving at night, the subjective correlate of macular pigment
  • Visual comfort during prolonged screen work
  • Digestive tolerance during the first four weeks of escalation
  • Any new bruising, gum bleeding or nosebleeds, which warrants immediate cessation
  • Sleep quality and daytime energy, acknowledging these were measured only in manufacturer-run trials